Health & Science

Eli Lilly Beats Q1 on Mounjaro Surge, Raises Guidance to $63 Billion as GLP-1 Capacity Doubles

Eli Lilly reported Q1 2026 revenue of $14.8 billion, beating consensus by $620 million on continued Mounjaro/Zepbound momentum, and raised full-year guidance to $63 billion at the midpoint as new manufacturing capacity in Indiana and Ireland came online.

Michael Torres•5/4/2026

us-marketshealth-science

Eli Lilly Tops $1 Trillion Market Cap as Orforglipron Phase 3 Hits Primary Endpoint

Eli Lilly became the first pharmaceutical company to surpass a $1 trillion market capitalization Thursday after the ATTAIN-1 Phase 3 trial of oral orforglipron showed 14.7% mean weight loss at week 72, paving the way for an FDA filing as soon as the third quarter.

Lisa Park•4/29/2026

us-marketshealth-science

Eli Lilly Q1 Beats on Mounjaro and Zepbound Demand, Raises 2026 Guidance to $63 Billion

Eli Lilly reported first-quarter earnings of $4.62 per share, an 18-cent beat, as combined Mounjaro and Zepbound sales reached $14.2 billion and management raised the 2026 revenue guide to $61-$63 billion from $58-$60 billion, sending shares up 3.4% in pre-market trade.

James Mitchell•4/29/2026

us-marketshealth-science

Eli Lilly Stock Surges 11% as Orforglipron Phase 3 Trial Hits All Endpoints in Oral GLP-1 Breakthrough

Eli Lilly shares surged 11.4% to $920 after the company reported Phase 3 results showing oral GLP-1 candidate orforglipron achieved 16.2% weight loss at 72 weeks while meeting all secondary cardiovascular endpoints.

James Mitchell•4/25/2026

us-marketshealth-science

Aligos Therapeutics Secures China Licensing Deal for Hepatitis B Drug, Opening Pathway to World's Largest HBV Market

Aligos Therapeutics has entered into an exclusive licensing agreement with China's Xiamen Amoytop Biotech to develop and commercialize pevifoscorvir sodium — its lead antiviral drug candidate for chronic hepatitis B virus infection — in Greater China, unlocking access to a market where more than 85 million people live with chronic HBV.

Maria Santos•4/16/2026

Trending Now

Target and Costco Advance as Consumer Names Defy the Energy Cost Shock

us-marketsfinance

Homebuilders Stay Flat Despite Bond Rally as Affordability Concerns Override Lower Long Yields

us-marketseconomy

Bitcoin Dominance Hits 58.6% as Total Crypto Market Cap Falls on a Rising Bitcoin

cryptotech

Airlines Slip as Jet Fuel Costs Climb With Crude Above $102

us-marketsfinance

Euro Falls to $1.1554 as Rate Differentials Swing Back Toward the Dollar

forexeconomy

Eli Lilly Leads Healthcare Higher as Investors Seek Shelter From Cyclical Exposure

us-marketsfinance

Defense Contractors Firm as Oil Spike Revives Geopolitical Risk Premium

us-marketspolitics

Copper Slides 2.6% and Caterpillar Drops 3.9% in a Warning on Global Industrial Demand

commoditieseconomy

Eli Lilly Beats Q1 on Mounjaro Surge, Raises Guidance to $63 Billion as GLP-1 Capacity Doubles

Eli Lilly Tops $1 Trillion Market Cap as Orforglipron Phase 3 Hits Primary Endpoint

Eli Lilly Q1 Beats on Mounjaro and Zepbound Demand, Raises 2026 Guidance to $63 Billion

Eli Lilly Stock Surges 11% as Orforglipron Phase 3 Trial Hits All Endpoints in Oral GLP-1 Breakthrough

Aligos Therapeutics Secures China Licensing Deal for Hepatitis B Drug, Opening Pathway to World's Largest HBV Market

Trending Now

Target and Costco Advance as Consumer Names Defy the Energy Cost Shock

Homebuilders Stay Flat Despite Bond Rally as Affordability Concerns Override Lower Long Yields

Bitcoin Dominance Hits 58.6% as Total Crypto Market Cap Falls on a Rising Bitcoin

Airlines Slip as Jet Fuel Costs Climb With Crude Above $102

Euro Falls to $1.1554 as Rate Differentials Swing Back Toward the Dollar

Eli Lilly Leads Healthcare Higher as Investors Seek Shelter From Cyclical Exposure

Defense Contractors Firm as Oil Spike Revives Geopolitical Risk Premium

Copper Slides 2.6% and Caterpillar Drops 3.9% in a Warning on Global Industrial Demand

Market Movers